Ivermectin reduces alcohol intake and preference in mice.
The high rate of therapeutic failure in the management of alcohol use disorders (AUDs) underscores the urgent need for novel and effective strategies that can deter ethanol consumption. Recent findings from our group showed that ivermectin (IVM), a broad-spectrum anthelmintic with high tolerability and optimal safety profile in humans and animals, antagonized ethanol-mediated inhibition of P2X4 receptors (P2X4Rs) expressed in Xenopus oocytes. This finding prompted us to hypothesize that IVM may reduce alcohol consumption; thus, in the present study we investigated the effects of this agent on several models of alcohol self-administration in male and female C57BL/6 mice. Overall, IVM (1.25-10 mg/kg, intraperitoneal) significantly reduced 24-h alcohol consumption and intermittent limited access (4-h) binge drinking, and operant alcohol self-administration (1-h). The effects on alcohol intake were dose-dependent with the significant reduction in intake at 9 h after administration corresponding to peak IVM concentrations (C(max)) in the brain. IVM also produced a significant reduction in 24-h saccharin consumption, but did not alter operant sucrose self-administration. Taken together, the findings indicate that IVM reduces alcohol intake across several different models of self-administration and suggest that IVM may be useful in the treatment of AUDs.
PubMed ID: 22465817
PMC ID: PMC3372603
Article link: Neuropharmacology.
Grant support: AA013517 NIAAA NIH HHS , AA013922 NIAAA NIH HHS , F31AA018926 NIAAA NIH HHS , KO-1-AA017243 NIAAA NIH HHS , R01 AA013922-05 NIAAA NIH HHS , UL1 TR000130 NCATS NIH HHS , F31 AA018926-03 NIAAA NIH HHS , K01 AA017243-04 NIAAA NIH HHS , R01 AA013922 NIAAA NIH HHS
Genes referenced: p2rx4